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Original Article42
Amaç: Akromegali hastalarında kemik mineral densitometre (KMD) ve periodontit varlığını ve etkileşimde bulunan faktörleri değerlendirmek. 
Gereç ve Yöntem: Kalsiyum-kemik metabolizmasını etkileyen durumu olmayan 47 akromegali olgusu ve 60 yaş-cinsiyet eşleşmiş sağlıklı olgu 
çalışmaya alındı. Yaş, cinsiyet, akromegali süresi ve aktivitesi, geçmiş ve güncel tedaviler, hipofiz hormon profilleri ve replasman tedavileri, 
periodontal analiz sonuçları kaydedildi.
Bulgular: Yaş ortalamaları 46,6±11,5 yıl olan 18 erkek (%38,3), 29 kadın (%61,7) olgunun 25’inin (%53,1) aktif, 22’sinin (%46,8) inaktif hastalığı vardı. 
İnaktif hastalık grubu daha yaşlı idi, hastalık süreleri daha uzundu, sırası ile; p=0,04, p=0,003. Serum kalsiyum, fosfor düzeyleri, 24 saatlik idrar 
kalsiyum atımları, femoral ve lomber KMD değerleri ile hastalık aktivitesi ilişkisizdi (p>0,05). Altı hastada (%12,76) osteoporoz saptandı. Periodontit 
kontrol grubunda daha sık izlendi; %66,7 ve % 44,7, bu grupta ağırlıklı olarak şiddetli periodontit görüldü; %43,3 ve %12.8, (sırası ile; p=0,022, 
p=0,0001). Kronik periodontit sıklığı ve şiddeti, aktif ve inaktif akromegali grupları arasında farksızdı; %48 ve %40,9 (p=0,279). Tekrarlayan 
değerlerin varyans analizi testinde, zaman içinde büyüme hormonu değişimi ve periodontit alt grupları anlamlı dağılım göstermedi (p>0,05).  
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Purpose: To evaluate bone mineral density (BMD) measurements and the presence of periodontitis in patients with acromegaly, as well as to 
inquire the impact of interfering factors. 
Material and Method: Forty-seven acromegalic patients with any accompanying condition known to affect calcium-bone metabolism and 60 
age-matched healthy controls were included. Age, gender, duration and activity of acromegaly, past-present therapy options, pituitary hormone 
profiles, replacement therapies, and the results of periodontal analysis were recorded. 
Results: Eighteen patients were male (38.3%), 29 were female (61.7%). The mean age of the patients was 46.6±11.5 years, twenty-five (53.1%) 
had active, 22 (46.8%) had inactive acromegaly. The latter were older and had longer disease duration (p=0.04, p=0.003, respectively). Serum 
calcium and phosphorus levels, 24-hour urinary calcium excretion and BMD at the lumbar spine and femur neck insignificantly associated with 
disease activity (p>0.05). Osteoporosis was detected in 6 patients (12.76%). Periodontitis and advanced periodontitis were more common in 
control group (66.7% vs. 44.7%), (43.3% vs. 12.8%) (p=0.022, p=0.0001, respectively). There was no difference in chronic periodontitis and severity 
between active and inactive groups (48% vs. 40.9%; p=0.279). No difference was noted in other study parameters, as well. Repeated measures 
analysis of variance demonstrated statistically insignificant distribution between GH change in time and periodontitis subgroups.  
Discussion: We demonstrated that acromegaly exerted no clear negative impact on vertebral BMD in the absence of overt hypogonadism. 
Regardless of disease activity, acromegaly cases exhibited lower rates of periodontitis with less severity which remained unchanged in the 
presence of accompanying metabolic disorders known to have negative impact on periodontal tissue. Chronic exposure to excess GH may have 
a protective role against periodontitis. Turk Jem 2015; 19: 42-48
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Introduction 
Acromegaly is a disorder characterized by growth of many tissues 
due to uncontrolled oversecretion of growth hormone (GH) and 
insulin-like growth factor-1 (IGF-1) (1). Both GH and IGF-1 play 
important roles in calcium and bone metabolism at many steps. 
For instance, IGF-1 activates renal 1-hydroxylase enzyme and 
inhibits 24-hydroxylase, thus, increases serum calcitriol. 
Acromegaly causes periosteal new bone formation, cortical 
thickening of the diaphysis of the long bones and joint space 
widening. Bone mineral density (BMD) is usually unpredictable 
due to interfering factors, predominantly accompanying 
hypogonadism in acromegaly (2,3). Eugonadal acromegalic 
patients exhibit increased cortical bone BMD at the distal radius, 
whereas spinal trabecular bone usually demonstrate insignificant 
change (4). In eugonadal acromegalic patients, serum osteocalcin, 
urinary hydroxyproline and pyridinoline levels are detected to be 
high and lumbar BMD values are within normal limits (5). 
In acromegaly, osteoporosis is usually due to accompanying 
hypogonadism and results in decrease in lumbar vertebral 
BMD. Disease duration, serum IGF-1 levels and hypogonadism 
predict the prevalence of vertebral fractures (VF) (1,3). However, 
a high rate of  incident VF has been reported in both active and 
controlled acromegalic patients. In a recent study, progression 
of VF has been documented in 20% of cases, despite long-term 
biochemical control of acromegaly. Progression of VF has not 
been detected to relate with BMD values or BMD changes over 
time (6). 
Besides frontal bossing and changes in the lips and nose, 
growth of the mandibular bone, separation of the teeth, maxillary 
widening, and malocclusion of the mouth are frequently 
observed in acromegaly (1). Tooth mobility and loss, interdental 
spaces (diestema), and, rarely, gingival overgrowth are detected 
at periodontal examination. There is scant data about the 
periodontal findings in cases with acromegaly. 
Periodontal disease is a localised inflammatory reaction of the 
tissues surrounding the teeth against bacterial infections (7). 
Its presence may be a risk factor for ischemic heart disease, 
pulmonary diseases, premature labor, and low birth weight. 
Other risk factors associated with periodontal disease are 
smoking, traumatic occlusion of the mouth and diabetes mellitus 
(8). It is the second well-identified cause for tooth loss and usually 
accompanies systemic diseases and is mainly separated into two 
main groups; gingivitis and periodontitis. 
Gingivitis is an immune response against the microbial dental 
plaque located on the teeth and affects more than 90% of the 
population. Smoking, medications, pregnancy and hormonal 
changes during puberty may act on gingiva. Destruction is limited 
to gingiva and is reversible. Gingiva is found to be edematous 
and hyperemic (7,9). However, periodontitis is characterised by 
irreversible injury in periodontal tissues. Diestema and prominent 
tooth mobility are clear signs of periodontitis. Increment in 
probing depth, loss of attachment and demonstration of bone 
loss radiographically are required for the diagnosis. Periodontitis 
is a multifactorial disease and presence of periodontopathogenic 
bacteria is not the only factor necessary for its initiation and 
progression (10). Systemic diseases; cardiovascular diseases, 
diabetes mellitus, syndromes associated with neutropenia, 
rheumatoid arthritis, medications, and accompanying genetic 
and environmental factors may impact the pathogenesis of 
periodontitis and the response of the host to therapy (11). 
Studies inquiring the association between periodontitis and 
systemic bone density reveal that subjects with low bone density 
have less number of teeth, more clinical attachment loss and 
more periodontitis. Low systemic bone density has been proposed 
to be a risk factor for progression of alveolar bone loss and has 
been claimed to increase vulnerability to periodontal destruction. 
An association has also been shown between serum estrogen 
levels and alteration in alveolar bone mineral density among 
post-menopausal women (12,13,14). 
High serum GH, IGF-1, insulin-like growth hormone-binding 
protein-3 (IGF-1BP-3) and calcitriol levels directly act on bone and 
connective tissue in acromegaly. Accompanying hypogonadism, 
defects in glucose metabolism, malabsorption due to somatostatin 
analogues, which are used in acromegaly treatment, may all 
adversely affect the periodontal structures and bone. Besides 
hormonal changes, duration and activity of the disease may affect 
the course of periodontitis (5,15,16). 
In this study, we aimed to evaluate BMD and the presence of 
periodontitis in patients with acromegaly and to inquire the impact 
of interfering factors. 
Materials and Methods 
This study was performed at outpatient endocrinology clinics of 
Başkent University Faculty of Medicine, Adana, Turkey between 
August 2010 and November 2012. 
A total of 47 patients with the diagnosis of acromegaly and 60 
age-matched healthy controls were included for periodontal 
analysis. The study was approved by the Local Ethics Committee 
(tracking #: K09/330) and all participants gave written informed 
consent. 
The exclusion criteria included having any condition known 
to affect calcium and bone metabolism, such as being on 
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levothyroxine suppression therapy due to differentiated thyroid 
carcinoma, chronic renal failure, hyperparathyroidism, untreated 
hypothyroidism and/or hypocortisolism, and bisphosphonate 
use. As smoking is known to negatively affect periodontal health, 
it was regarded as an exclusion criterion, as well. Additionally, the 
participants were instructed not to use any interfering medication, 
such as anti-inflammatory and immune-suppressive drugs 
throughout the study period. 
Physical examination was performed and all the exclusion criteria 
were also applied for the participants in control group. 
An acromegalic male with central hypogonadism who used 
testosterone replacement therapy irregularly and another 
male with cured acromegaly who had celiac disease were not 
included. Two other acromegalic males with active disease were 
also excluded because of their total prosthesis. 
The patients were evaluated regarding age, gender, duration and 
activity of acromegaly, past therapy options; medical, surgical, 
radiotherapy, combination therapies, current medical agents, 
pituitary hormone profiles, and replacement therapies. 
Active acromegaly was defined if randomly measured GH was 
above 2.5ng/dl and IGF-1 above age-corrected limits with/without 
medical treatment. Patients with discordant measurements were 
considered as active, as well. Other pituitary functions were 
determined by evaluating pituitary hormones with end organ 
responses and performing dynamic tests where required (17). 
Accompanying glucose metabolism disorders; impaired fasting 
glucose, impaired glucose tolerance as well as diabetes mellitus, 
hypertension and cardiovascular disease were also recorded. 
In study group, patients who were on levothyroxine treatment 
due to central hypothyroidism with normal free thyroxine levels 
were considered euthyroid. Premenopausal women with central 
hypogonadism who were on cyclic estrogen/progesterone 
therapy were regarded as eugonadal as well as the men who 
were on testosterone replacement therapy with normal serum 
testosteron levels. 
Serum calcium, phoshporus and 24-hour urinary calcium 
excretion levels were measured. BMD measurement was 
performed at the femoral neck and lumbar spine. 
Study and control groups were both subjected to periodontal 
examination. Periodontal examinations were performed by 
the same experienced periodontist. Periodontal pocket depth 
(presence of an abnormal gingival sulcus near the point at which 
the gums contact a tooth) was evaluated using periodontal probe 
at six different points of each tooth. Individuals with probing pocket 
depth (PPD) between 4 mm and 6 mm and clinical attachment 
level of (CAL=amount of space between attached periodontal 
tissues and a fixed point, usually the cementoenamel junction) 
up to 4 mm were diagnosed as having chronic periodontitis with 
slight to moderate loss of periodontal support. Those with PPD 6 
mm and CAL greater than 4 mm were regarded as having chronic 
periodontitis with advanced loss of periodontal support. Bleeding 
on probing, which was considered as an objective inflammatory 
parameter in periodontitis establishment, was measured using 
the gingival bleeding index (GBI). A GBI of ≤0.1 was considered 
low risk for the development of periodontitis. Tooth mobility levels 
were evaluated and classified as degrees; 1, 2, 3. Radiographic 
examination, tooth loss, diastemas (space or gap between two 
teeth) and malocclusion were also assessed (18,19). 
Laboratory Analyses and BMD Measurements 
GH measurements were performed with immunometric assay 
(Immulite Growth Hormone, Diagnostic Products Corp., CA, USA), 
IGF-1 measurements were done with highly sensitive and specific 
immunoradiometric methods (Diagnostic Systems Laboratories, 
DSL -5600 ACTIVE). Serum calcium and 24-hour urinary calcium 
excretion levels were determined using the colorimetric method 
(Roche Modular P-Roche). Serum phosphorus was analysed via 
phosphomolibdate method (Architect C16000-ABBOTT). 
BMD measurements were performed using dual energy x-ray 
absorptiometry (DXA) (Hologic QDR 4500, Hologic IIc., Waltham, 
MA, USA) at the lumbar vertebra (L1-L4) and femur neck. T and Z 
scores were evaluated using the new NHANES III reference criteria. 
Osteopenia (a T score between -1 and -2.5) and osteoporosis (a 
T score of  less than 2.5) were defined according to the criteria of 
the World Health Organization. 
Statistical Analysis 
The SPSS software (Statistical Package for the Social Sciences, 
version 17.0, SSPS Inc, Chicago, IL, USA) was used for statistical 
analyses. Categorical variables were given as number and 
percentage, continuous variables are presented as means ± 
SD, if distributed normally and as median - minimum-maximum, 
if distributed not normally. Standard descriptive analysis, 
independent samples T-test, the  Wilcoxon test, Chi-square, 
Mann-Whitney U test, Spearman’s correlation coefficient, and the 
repeated measures ANOVA were used where appropriate. A p 
value of less than 0.05 was considered statistically significant. 
Results 
A total of 47 acromegalic patients [18 males (38.3%) and 29 
females (61.7%)] with a mean age of 46.6±11.5 years were 
included in study. Fourteen subjects (29.8%) were on medical 
therapy only, whereas 33 (70.2%) were subjected to combination 
therapy, i.e medical therapy following surgery (24-72.2%), medical 
therapy following radiotherapy (1-2.1%), and medical therapy 
following surgery and radiotherapy (8-24.2%). Of the cases on 
medical therapy only; 23 patients (48.9%) were using octreotide, 
21 (44.7%) were on octreotide and cabergoline; dopamine agonist 
simultaneously, and 3 (6.4%) patients were using pegvisomant 
only. 
Hormonal assessment of disease activity revealed that 25 
(53.1%) patients had active acromegaly, whereas 22 (46.8%) 
had inactive disease. Inactive acromegaly group was older and 
had longer disease duration (p=0.04 and p=0.003, respectively). 
Serum calcium and phosphorus levels, 24-hour urinary calcium 
excretion and BMD values at the lumbar spine and femur neck 
exhibited insignificant difference between the active and inactive 
acromegaly groups. Details are given in Table 1. 
Twenty-one patients (44.7%) had glucose metabolism disorder at 
various severities. Twenty cases (42.6%) had hypertension and two 
(4.3%) had cardiac disease. Active and inactive disease groups 
did not differ regarding therapeutic options, glucose metabolism 
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disorders and cardiac disease (p=0.457, p=0.202, p=0.123, 
respectively), however, more patients in active acromegaly group 
had hypertension, as might be expected (p=0.042). 
Among 13 female cases with active disease, nine (69.2%) were 
premenopausal, whereas seven (43.8%) were premenopausal 
among 16 female cases with inactive acromegaly (p=0.264). 
Postmenopausal cases were older (57.1±5.1 years vs. 37.7±5.5 
years) and had longer duration of disease [median: 6 (1-17) years 
versus median: 2 (1-12)], as may be expected (p=0.039 and 0.001, 
respectively). However, they exhibited statistically indifferent 
lumbar and femur BMD measurements regarding to disease 
activity and menopausal status (p=0.964, p=0.94 and p=0.188, 
p=0.469, respectively). 
Osteoporosis was detected in 6 subjects (12.76%) in study group. 
One acromegalic man exhibited low femur bone density, whereas 
five patients-two premenopausal and three postmenopausal 
women-demonstrated osteoporosis at the lumbar spine. 
Periodontal examination findings in acromegaly and control 
groups (n=60) were evaluated. Twenty-six patients with 
acromegaly (55.3%) did not exhibit periodontitis. Of 21 patients 
(44.7%) with acromegaly and periodontitis; 15 (31.9%) had slight to 
moderate periodontitis and 6 (12.8%) had advanced periodontitis. 
Twenty-two acromegalic patients (46.8%) exhibited macroglossi. 
More number of cases had periodontitis in control group, 
advanced periodontitis being dominantly (p=0.022 and p=0.0001, 
respectively). Details are given in Table 2. 
There was no difference in the total number of cases with chronic 
periodontitis between active and inactive acromegaly groups 
(48% vs. 40.9%) (p=0.279). There was no statistically significant 
difference in severity of periodontitis between the groups, as well 
(details are shown in Table 3). The presence of periodontitis also 
exhibited any relationship with menopausal state (p=0.521 ). There 
was not a relationship between the presence of periodontitis and 
menopausal state.
Besides similar periodontal findings, active and inactive 
acromegaly groups exhibited statistically insignificant difference 
with regard to calcium-BMD analyses. 
Study parameters in acromegaly patients (n=47) were compared 
with regard to periodontal disease and its severity; 26 subjects 
were without periodontitis, 15 were  with slight to moderate 
periodontitis  and 6 patients were with advanced periodontitis. 
There was no difference between the groups in terms of serum 
calcium and phosphorus levels, final GH and IGF-1 levels, 
presence of hypertension, glucose metabolism disorder and/or 
cardiac disease (p=0.121, p=0.604, p=0.590, p=0998, p=0.253, 
p=0.081, and p=0.782, respectively). 
Considering the negative impact of glucose metabolism disorders 
on periodontal structures, acromegaly cases were compared with 
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Tablo 3. Distribution of periodontitis in acromegaly group regarding disease activity
n Cases without periodontal 
pathology (n)
Cases with slight to moderate chronic 
periodontitis (n)
Cases with advanced 
periodontitis (n)
Active Acromegaly 25 13 7 5
Inactive Acromegaly 22 13 8 1
   p 0.625 0.539 0.113
Table 1. Comparison of general features and bone parameters of 
active and inactive acromegaly patients 
Disease activity
(n=47)
Active group 
(n=25)
Inactive group 
(n=22)
p
Age (years) 43.4±11.4 50.32±10.7 0.040
Gender (F/M) (%) 52/48 72.7/27.3 0.229
Duration of acromegaly 
(year)
2 (1-10) 5 (2-17) 0.003
Serum GH (ng/ml) 4.01 (0.38-56) 0.82 (0.09-2.4) 0.0001
Serum IGF-1 (ng/ml) 417 (232-1356) 173 (57-252) 0.0001
Serum Ca (mg/dl) 9.44±0.38 9.44±0.42 0.989
Serum P (mg/dl) 4.19±0.66 3.93±051 0.143
Urinary Ca (mg/day) 105 (10-380) 105 (10-300) 0.134
Lumbal T score (total) -0.9 (-4.0-2.0) -0.65 (-4.0-2.0) 0.842
Femoral neck T score -0.10 (-3.0-2.0) -0.1 (-2.0-2.0) 0.375
GH: Growth hormone, IGF-1: Insulin like growth hormone-1
Mean ± Standard Deviation, Median (Minimum-Maximum)
Table 2. Documentation of general features and periodontological 
examination of Acromegaly group and Control group
Acromegaly 
group 
(n=47)
Control 
group 
(n=60)
p
Age (year) 46.6±11.5 50.32±8.5 0.146 
Gender (F/M) (n) 29/18 34/26 0.599
Active/Inactive  
Acromegaly (n/n)
25/22 - -
Glucose Metabolism  
Disorder n (%)
21/47 (44.7) - -
Cases without periodontitis  
 n (%)
26/47 (55.3) 20/60 (33.3) 0.023
Total # of chronic 
periodontitis n (%) 
21/47 (44.7) 40/60 (66.7) 0.022
Slight to moderate 
periodontitis n (%)
15/47 (21.9) 14/60 (23.3) 0.321
Advaced periodontitis  n (%) 6/47 (12.8) 26/60 (43.3) 0.0001
Macroglossi n (%) 22/47 (46.8) - -
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regard to the presence of glucose metabolism disorder. Keeping 
in accordance with the literature, 13 (61.9%) of 21 patients with the 
disorder was found to have chronic periodontitis, while 8 (38.1%) of 
26 patients with normal glucose metabolism had periodontitis of 
various severity (p=0.043). Presence of other metabolic disorders, 
i.e. hypertension or cardiac disease, was found not to associate 
with periodontitis. 
By taking a T score of 0 as the cut-off value, acromegaly cases 
were grouped as the ones with or without osteoporosis/
osteopenia. Twenty-seven patients (57.4%) had lumbar 
osteoporosis/osteopenia, whereas femoral osteoporosis/
osteopenia was detected in only 15 subjects (31.9%). Disease 
activity exhibited no impact on the presence of osteoporosis/
osteopenia at lumbar and femoral BMD (p=0.533 and p= 0.177, 
respectively). Presence of periodontitis did not show a relationship 
with osteoporosis/osteopenia at either site, as well (p=0.369 and 
p=0.549). Repeated measures analysis of variance performed to 
investigate the relationship between the GH change in time at 
least three sequential time points and periodontitis subgroups 
exhibited (GH change in time at least three sequential time points 
and periodontitis subgroups), statistically insignificant distribution 
[GH (median: minimum-maximum); GH1: 10.0 (0.52-40.0), GH2: 
6.89 (0.38-200), GH3: 4.53 (0.35-56)]. 
Discussion 
GH has been demonstrated to act on bone via interacting directly 
on GH receptors on osteoblasts and via increasing local IGF-1 
production (autocrine and paracrine effect). IG-1 contributes 
to the differentiation of osteoblasts. GH deficiency has been 
demonstrated to associate with bone loss and osteoporosis, 
however, the impact of excess GH on bone tissue is less clear 
(20,21,22). In the present study investigating bone density and 
periodontital tissue, a new site of trabecular bone, among 
acromegaly cases, no statistically difference was found between 
active and inactive acromegaly subgroups in serum calcium 
and phosphorus levels, urinary calcium excretion and BMD 
measurements in the presence of similar rates of periodontitis. 
Periodontitis has been detected less frequently with less severity 
in study group. Severity of periodontitis has also been shown 
not to associate with accompanying metabolic problems, e.g., 
hypertension, cardiac disease or glucose metabolism disorder, 
and with biochemical and hormonal parameters, such as serum 
calcium, phosphorus, GH and IGF-1 levels and menopausal 
status. Thus, acromegaly seems to exert a protective effect against 
periodontitis with neutral effect on vertebral BMD in the absence 
of overt hypogonadism. 
Active acromegaly in the presence of  high serum GH and IGF-1 
levels have been shown to impair bone quality and increase 
the risk of bone fragility. It has been detected to associate with 
hypercalciuria and negative calcium balance (23). High bone 
turnover has been detected by measuring changes in biochemical 
markers of bone metabolism and histomorphometry among 
acromegalic patients. 
Markers for bone turnover, predominantly the resorption 
markers, have been shown to increase and the latter have been 
demonstrated to correlate positively with serum GH and IGF-1 (24). 
However, keeping in accordance with our findings, the negative 
effects mentioned above have not been shown in DXA-BMD 
measurements and normal or even high bone density has also 
been demonstrated in acromegaly (25). 
We have performed a liberal selection bias for excluding 
hypogonadism and found out that disease activity exhibited 
no clear impact on BMD in acromegaly. In addition, there was 
no statistically significant difference between pre-menopausal 
acromegalic patients and their older postmenopausal peers 
in BMD values. Our finding is compatible with the literature 
reporting the neutral effect of acromegaly on vertebral BMD in 
the absence of hypogonadism (4,5). However, one can argue 
that inactive acromegaly cases and the postmenopausal ones 
in this study were older and naturally had longer duration of 
disease, thus, this may have blunted their axial BMDs. DXA, the 
method we performed is currently the most commonly used one 
for determining bone health. However, it has some limitations. 
Atherosclerotic plaques, vertebral deformities and osteoarthritis 
may cause falsely high BMD measurements. Besides, DXA 
measures areal BMD-grams per square centimeter - and 
its 2-dimensional (2D) BMD measurement may probably be 
negatively affected by bone enlargement in acromegaly. It also 
does not give details about cortical and trabecular bone and 
bone micro-architecture which are very important for fracture 
risk assessment (24). High-resolution quantitative computed 
tomography (HR-QCT) is a method that permits the in vivo 
assessment of the bone micro-architecture and the volumetric 
BMD. Its measurements are comparable to 2D histomorphometry 
and 3D microcomputed tomography of transiliac bone biopsies 
(25). In a very recent study, the negative effect of acromegaly has 
been demonstrated on trabecular bone microarchitecture using 
HR-QCT in the distal radius and tibia in eugonadal patients. In 
that study, hypogonadism has been strictly defined and, besides, 
young acromegalics without sex hormone replacement therapy 
and postmenopausal women have also been excluded. This 
approach has resulted in a younger group of patients with shorter 
duration of disease and less contributing factors. However, the 
resultant relatively low number of participants necessitates this 
study to be re-performed on a larger number of eugonadal 
acromegalic patiens by using vertebral HR-QCT (26). 
We were unable to exclude our postmenopausal patients due 
to low number of participants and that may be considered as 
a limitation of our study. However, a complementary parameter, 
periodontal analysis, was performed in addition to DXA to 
investigate an additional area of trabecular-alveolar bone. 
We assume that lower rates of chronic periodontitis among 
acromegalic patients support the reliability of our DXA-BMD 
measurements. 
Our findings impose the idea that in the absence of overt 
hypogonadism, excess GH may not have a negative effect on 
trabecular BMD. Nevertheless, it should be kept in mind that 
normal BMD does not imply a risk-free profile for vertebral 
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fractures. Progression of VF in controlled acromegaly cases with 
normal BMD is a supportive observation for this proposal (6). 
Periodontitis is an important area of interest for periodontists 
due to the fact that it causes irreversible destructive injury to 
alveolar bone and the net effects of GH and IGF-1 on periodontal 
structures are not clear. Osteoblast are regulator cells of bone 
metabolism, they limit bone matrix synthesis or bone resorption 
under various conditions. Human periodontal ligament cells 
(PDL) act like osteoblasts; they are the master cells regulating 
the resorption and synthesis of connective tissue of periodontal 
structures (27,28). GH is an important factor acting on the gingival 
tissue and alveolar bone. Besides their effects on osteoblasts, GH 
and IGF-1 have been demonstrated to increase the secretion of 
bone morphogenic protein-2 (BMP-2) and bone morphogenic 
protein-4 (BMP-4) from human dental pulp fibroblasts (29). GH 
has been reported to increase alveolar bone formation in an 
experimental study on rat periodontium (30). Accordingly, in a 
recent study, acromegalic patients have been shown to exhibit 
less periodontitis (8). This effect may be partially attributed to the 
not negative impact of acromegaly on trabecular bone (4). The 
findings of our study are compatible with the data mentioned 
above. It is possible that chronic exposure to excess GH may 
even have a protective effect against periodontitis. Knowing that 
postmenopausal state is a risk factor for periodontitis, detection 
of similar number of postmenopausal and premenopausal cases 
with periodontitis in our cohort is a supportive data to the above 
mentioned data (14). After grouping our cases with regard to the 
presence of osteoporosis/osteopenia, it was observed that there 
was no difference in the prevalence of periodontitis between the 
groups. We were unable to demonstrate the protective effect of 
chronic excess GH exposure on the periodontal tissue statistically 
by using the repeated measures analysis of variances, however, 
we assume that if the number of acromegalic participants could 
be increased, the statistical significance would be evident. 
Our study has some limitations. The relatively low number of 
participants is one of them, and therefore we had to perform a 
liberal approach regarding the inclusion of hypogonadal patients.
Not performing HR-QCT and not measuring resorption markers 
are the other limitations. 
In conclusion, in the present study, we have demonstrated that 
acromegaly exerts no clear negative impact on vertebral BMD 
in the absence of overt hypogonadism. Regardless of disease 
activity, acromegaly cases exhibit lower rates of periodontitis 
with less severity which remains unchanged in the presence 
of accompanying metabolic disorders known to have negative 
effects on the periodontal tissue. Chronic exposure to excess 
GH may have a protective role against periodontitis. We believe 
this information requires to be confirmed by studies with larger 
sample sizes. 
Acknowledgement: Many thanks to Çağla Sarıtürk for her 
contribution for statistical analysis. 
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